Skip to main content

Table 2 Comparison of clinical treatment between STEMI patients during non-COVID-19 and COVID-19 pandemic periods

From: Reconsidering treatment guidelines for acute myocardial infarction during the COVID-19 pandemic

 

STEMI

p-value

Group 1 (n = 153)

Group 2 (n = 81)

Treatment place, n (%)

 Accident and emergency department

3 (2.0)

6 (7.4)

0.088

 In-hospital

150 (98.0)

75 (92.6)

 

Reperfusion therapy, n (%)

115 (75.2)

55 (67.9)

0.236

 Primary PCI

100 (65.4)

20 (24.7)

 < 0.001*

 Thrombolytic therapy

6 (3.9)

21 (25.9)

 < 0.001*

 Selective PCI

9 (5.9)

14 (17.3)

0.005*

 CABG

0 (0.0)

0 (0.0)

-

Conservative therapy, n (%)

38 (24.8)

26 (32.1)

0.236

First medical contact time (min), median (IQR)

111.0(55.0,282.0)

223.5 (118.8,567.3)

 < 0.001*

DTB time (min), median (IQR)

55.0(48.0,66.0)

67.5(50.3,116.3)

0.021*

Total myocardial ischemia time (min), median (IQR)

189.0(118.0,338.0)

383.5(198.0,654.0)

0.018*

  1. STEMI ST elevation myocardial infarction, COVID-19 coronavirus disease 2019, DTB door-to-balloon, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, IQR interquartile range
  2. *p < 0.05